Project Grant HT94252510914
Award Date 11/1/25
Completion Date 10/31/27
Dollars Obligated $695K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Sudbury, MA 01776, USA
Similar Awards
- This federal Project Grant award from the Department of Defense's Defense Health Agency (CFDA 12.420 - Military Medical Research and Development program) provides $1,383,586.00 to Byomass Inc. to support the development of BYOM-0322, a novel biologic agent targeting the TGF-beta superfamily. The purpose is to evaluate BYOM-0322 for the prevention and treatment of breast cancer metastases and cancer cachexia (muscle wasting). This 3-year grant, awarded on February 15, 2024, will fund Byomass...
- This $381,312.00 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) is funding research at the University of Massachusetts Medical School to determine the molecular etiology of and strategies to block pancreatic cancer cachexia. The award has a performance period from July 15, 2024 to July 14, 2027. The University of Massachusetts Medical School is the awardee and will be conducting the research through its Grants and...
- The Defense Health Agency awarded a $522,477 Project Grant to Boston Medical Center Corporation (BMC) under the Military Medical Research and Development program (CFDA 12.420). The funding will support research to define genetic vulnerabilities in pancreatic neuroendocrine tumors that rely on the alternative lengthening of telomeres pathway. This 3-year project grant runs from August 1, 2023 to July 31, 2026. A sub-award of an unspecified amount was provided to the Trustees of Boston...
- The Defense Health Agency awarded a $784,602 Project Grant to Dana-Farber Cancer Institute, Inc. (doing business as Dfci) under the Military Medical Research and Development program (CFDA 12.420). The grant will support research from January 2023 to January 2026 to develop next-generation immunotherapy for breast cancer by turning breast cancer cells against themselves. The Military Medical Research and Development program aims to transform military and public health through innovative medical...
- This federal Project Grant award of $707,438 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research to determine the molecular etiology of and strategies to block pancreatic cancer cachexia. The award was made on July 15, 2024 with a performance period ending on July 14, 2027. The prime awardee is the University of Massachusetts Medical School's Grants and Contracts Administration Division, which will conduct the research at their...
- The Department of the Army Medical Command awarded a $1,419,356 project grant to Brigham & Women's Hospital Inc. under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from September 2021 through September 2025 to develop novel immunotherapy approaches to suppress cancer metastasis and recurrence in bone. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research with the goals of...
- The Defense Health Agency has awarded a $657,263 project grant under the Military Medical Research and Development program (CFDA 12.420) to the Dana-Farber Cancer Institute, Inc. (d.b.a. DFCI) in Boston, MA. The award, effective September 1, 2024 through August 31, 2027, will support DATA-DRIVEN BIOMARKER-INFORMED DECISION ANALYTICS IN MELANOMA: IMPROVING EFFICACY AND REDUCING TOXICITY OF IMMUNE CHECKPOINT BLOCKADE. Through this grant, DFCI will conduct research to develop data-driven...
- The Department of Defense (DoD) has awarded a $846,000 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to The Institute For Cancer Research, a non-profit research organization, to investigate PALB2 mutant breast cancer. The funding supports a 3-year research project from August 1, 2024 to July 31, 2027. As the prime grantee, The Institute For Cancer Research will conduct innovative scientific studies and clinical trials focused on developing new treatments...
- The federal Project Grant award titled "COMMUNICATION BETWEEN CANCER-ASSOCIATED FIBROBLASTS AND NEURONS PROMOTES PANCREATIC CANCER PROGRESSION" was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The $518,342 award was granted to the Cold Spring Harbor Laboratory (CSHL), a prestigious non-profit research institution, to conduct advanced biomedical research focused on investigating the relationship between...
- The Defense Health Agency awarded $780,749 to Health Research, Inc. Roswell Park Division under the Military Medical Research and Development federal grant program (CFDA 12.420) to support research into novel combination immune therapy regimens for metastatic breast cancer. The three-year project grant, beginning February 1, 2023, will fund the development of innovative medical solutions through basic, applied, and advanced biomedical research. Specifically, the awardee will investigate new...